drugset / Trial / NCT00484341
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.
RandomizedParallel-groupOpen-labelTreatment
Summary
The main objective of the trial is to document the preliminary antitumor activity of two doses of NGR-hTNF administered either alone or in combination with doxorubicin in locally advanced or metastatic soft-tissue sarcoma (STS) patients untreated or previously treated with one or more prior systemic regimen.
Timeline
- Start
- 2010-10
- Primary completion
- 2016-05
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |
| Subject | NGR-hTNF | Protein / enzyme biologic | 0.8 ug/m2 | Intravenous |
| Subject | NGR-hTNF | Protein / enzyme biologic | 45 ug/m2 | Intravenous |